ArticleBMC infectious diseases2026
Trends in candidemia and antifungal resistance: a nine-year single-center study in Turkey.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandidemia is a major global health concern with rising incidence and mortality. Regional surveillance is essential, as species distribution and antifungal resistance vary significantly.
methodsWe analyzed 541 Candida isolates from blood cultures at Cerrahpaşa Medical Faculty Hospital (2015–2023). Identification was performed using phenotypic methods, API 20 C AUX, BD Phoenix YEAST ID, and MALDI-TOF MS. Antifungal susceptibility was tested by gradient test (E-test) on RPMI agar, interpreted according to EUCAST guidelines for azoles, echinocandins, and amphotericin B.
resultsThe most frequent isolates were C. albicans (n = 214, 39%; susceptibility tested in 150), C. parapsilosis (n = 164, 29%), C. glabrata (n = 47, 7%), C. tropicalis (n = 42, 7%), and C. krusei (n = 10, 2%). Other species accounted for 16% (n = 64), including cryptic species such as C. auris (n = 9) and C. haemulonii (n = 1). The total cases were 269 in the pre-COVID period and 272 in the COVID and post period, chi-square analysis indicated these differences were not statistically significant (χ²=7.43, df = 6, p = 0.283). Increased MIC values against azoles were significantly detected in C. glabrata isolates, while C. parapsilosis complex generally exhibited a relatively high MIC distribution and a decreased susceptibility pattern. C. krusei demonstrated intrinsic resistance to fluconazole but remained susceptible to voriconazole.
conclusionsOur findings demonstrate a shift, though not statistically significant, toward non-albicans Candida species with emerging azole resistance, including the detection of multidrug-resistant C. auris. These trends underscore the need for enhanced local surveillance, molecular diagnostics, and evidence-based antifungal stewardship to optimize patient outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.